Profile: Xeris Pharmaceuticals, Inc.

Xeris is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, a proven therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris has a pipeline of development and partnered programs using its formulation sciences to support long-term product development and commercial success.

• Kathleen J. Chavanu, PharmD., BCMAS
  VP, Medical Communications & Regional Medical Affairs
• Mike Ferko
  Senior Manager, Strategic Trade